Patent ID: 8329879

Claim:
A method of manufacturing H 3 LMN compounds having the structural formula wherein R is selected from the group consisting of (CH 2 ) 13 CH 3 , (CH 2 ) 15 CH 3 and (CH 2 ) 15 COOC 2 H 5 , used as a precursor for the production of radioactive agents for treatment of liver cancer, comprising the steps of: obtaining 2-[(triphenylmethyl)thio]ethylamine by a reaction between 2-thioethylamine hydrochloride and CPh 3 ; obtaining N-[2-((triphenylmethyl)thio)ethyl] chloroacetamide by a transamidation reaction between 2-[(triphenylmethyl)thio]ethylamine) and chloroactyl chloride under existence of triethylamine; producing an amine-amide-thiol ligand-N-[2-((triphenylmethyl)thio)ethyl] [2-((triphenylmethyl)thio)ethylamino]acetamide by a reaction between 2-[(triphenylmethyl)thio]ethylamine and N-[2-((triphenylmethyl)thio)ethyl] chloroacetamide; and obtaining the H 3 LMN compounds having the formula wherein R is selected from the group consisting of (CH 2 ) 13 CH 3 , (CH 2 ) 15 CH 3 and (CH 2 ) 15 COOC 2 H 5 by a reaction of N-[2-((triphenylmethyl)thio)ethyl] [2-((triphenylmethyl) thio)ethylamino]acetamide with 1-bromotetradecane, 1-bromohexadecane and ethyl 16-bromo-hexadecanoate, respectively.